Kura Oncology and Kyowa Kirin Announce Global Strategic Collaboration to Develop and Commercialize Ziftomenib in Acute Leukemias
Portfolio Pulse from
Kura Oncology and Kyowa Kirin have entered a global strategic collaboration to develop and commercialize ziftomenib for acute leukemias. Kura will receive $330 million upfront and up to $1.2 billion in milestone payments. The companies will share profits 50/50 in the U.S., with Kura leading U.S. development and sales, while Kyowa Kirin will have exclusive rights outside the U.S.
November 20, 2024 | 10:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Kura Oncology enters a strategic collaboration with Kyowa Kirin to develop ziftomenib, receiving $330M upfront and up to $1.2B in milestone payments. This partnership will support Kura's AML program through commercialization.
The collaboration provides significant financial support and a strategic partner for Kura, enhancing its ability to advance its AML program. The upfront and milestone payments are substantial, indicating a positive short-term impact on Kura's financial position and stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100